Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Operating Expenses (2016 - 2025)

Lisata Therapeutics' Operating Expenses history spans 13 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 46.56% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $18.4 million, down 21.49%, while the annual FY2025 figure was $18.4 million, 21.49% down from the prior year.
  • Operating Expenses reached $3.2 million in Q4 2025 per LSTA's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $6.9 million in Q2 2023 to a low of $3.2 million in Q4 2025.
  • Average Operating Expenses over 3 years is $5.6 million, with a median of $5.9 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: fell 1.26% in 2024, then tumbled 46.56% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $6.0 million in 2023, then decreased by 1.26% to $5.9 million in 2024, then tumbled by 46.56% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Operating Expenses are $3.2 million (Q4 2025), $4.4 million (Q3 2025), and $4.9 million (Q2 2025).